Development of new proprietary preventive and therapeutic vaccine products. Zika, dengue and other flavivirus vaccines (technology platform). Sustainable and cost-effective therapies for the diseases of an ageing population. Strategic advice to Governments, NGOs and funding agencies on vaccine solutions. Re-thinking healthcare strategy for countries in 'demographic transition'.

Director Beraprost XR - developed long acting prostacyclin-drugs for the treatment of pulmonary hypertension. Established and managed collaboration with UCL.Director ...Hepatology Product Development - developed broad spectrum antiviral agents against HCV, HIV, dengue, influenza and filoviruses with high barrier to resistance, directed at host mechanisms. Managed collaboration with University of Oxford.

Advice for biotechnology and pharmaceutical companies and investors in the following areas. Previous clients include several listed and private companies in the UK, eg. as a consultant or Non-Executive Director:-• Business Plans - writing and contributing to business plans for start-up and mid-size biotechs including plans for AIM and main board listings• Non-Executive Directorship roles • Due Diligence for mergers and acquisitions and for technology / product candidate in-licensing• Business Development – campaign plans for out-licensing of products and technologies, virtual business development roles• Scientific / Ethical advisory boards – constitution and management• Portfolio Review – SWOT analysis, project triage and identification of new product opportunities, realize the full commercial potential of technologies and products• Grants – advice upon, or the writing of grant applications in collaboration with client• Programme/project management and assessment or selection of suitable contract research and manufacturing organizations (CROs/CMOs)• Advice to business angels, venture capital companies and institutions on biotech investments and new opportunities

Responsible for R&D and Business Development operations; pitching and managing collaborative projects with major pharma and biotech clients and granting agencies internationally; representing the outward face of the company at scientific and partnering conferences and with radio and TV; supporting fund-raising, licensing and contract negotiations; development of delivery-enhanced biologicals through early stage clinical trials; development of delivery platforms for siRNA, protein drugs and DNA vaccines; writing of patents and support of IP management; in fields of metabolic disease, oncology, anaemia management and nanotechnology.

Developed novel therapeutics and target validation strategies for neuropathic pain by targeted anatomically-specific delivery to the nervous system exploiting axonal transport. Procured EU grants and developed and managed research collaborations. Managed the company's IP portfolio. Co-author of business plan with CEO Tom Saylor netting £5.5M in VC funding.

In-licensed and developed group-A streptococcal vaccine and dental caries therapeutic products from Queensland Institute of Medical Research and Kings College London. In-licensed and developed (with Morten Isaksen, MD of Actigen Ltd. subsidiary) 'Covalent Display' platform for directed protein evolution of peptides and antibody fragments. Procured grants from the Department of Trade and Industry and the EU. Established and managed the Scientific and Ethical Advisory Board.

Early member of Peptide Therapeutics from Aston Science Park days through public listing on London Stock Exchange and beyond. Developed several peptide therapeutic and vaccine products through phase-I and phase-II trials. Introduced library technologies, group-B meningococcal vaccine and HSV-2 diagnostic projects. Developed molecular vaccine design platform. Managed all scientific aspects of flagship 'allergy vaccine' product development. Contributed to fund raising activities and investor relations. Contributed to a ~20 fold increase in company valuation. Involved in search for merger candidates, resulting in merger with Oravax that created 'Acambis plc' (now part of Sanofi Pasteur).

Conducted pioneering research into vaccines against bacterial and viral infections, and cancer. Established research programmes based on phage display as a technology platform for vaccine development. Developed vaccine candidates for meningococcal group-B infection, HSV-2 and breast cancer. Developed, devised and executed a successful experimental test of the 'teratogenic antibody theory' of schizophrenia', demonstrating that schizophrenia was more common in the offspring of cases of haemolytic disease of the newborn (caused by transplacental transmission of blood group antibodies). Procured grants to support this research from the MRC, Wellcome Trust, The Royal Society, Cancer Research Campaign and several charities.

Worked for Candace Pert (Head of Section on Brain Biochemistry), discoverer of the opiate receptor, and Steve Paul (Institute Director, NIMH) studying CNS autoimmune reactions provoked by virus infection as etiological factors in schizophrenia. Discovered a novel autoantigen (a brain-specific protein) targeted by autoantibodies evoked by influenza virus immunisation. Conducted neuropeptide research related to HIV dementia.

Studied cellular mechanisms of autoimmune diseases (including haemolytic anaemia) and developed two new methods for the detection of antigens. One of these, the luminescent Western blot method is used almost universally (in kit form) in biochemistry and immunology labs throughout the World.

Worked with Duncan Adams on endocrine autoimmune diseases in man. Demonstrated clonal restriction and specificity of thyroid stimulating (anti-TSH-receptor autoantibodies). Developed the first ELISA based assays for thyroid autoantigens. Proved that multiple co-existing endocrine autoimmune diseases were not caused by tissue cross-reactive autoantibodies. (The MRC Autoimmunity Research Unit, in pioneering clinical research, was largely responsible for the demonstration that autoimmunity was a novel mode of disease causation, and not just a consequence of infectious or degenerative disease aetiologies).